Physician profile
Daniel R Hoffman
NPI 1306853981
$1,131.63
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $592 · 2021: $113.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $212.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $155.81 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $143.14 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $139.82 | 2019-2020 | |
| Lilly USA, LLC | $132.24 | 2020-2021 | |
| Glaxosmithkline, LLC. | $97.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $71.38 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $59.22 | 2019 | |
| Esperion Therapeutics, INC. | $54.29 | 2020-2021 | |
| Gilead Sciences, INC. | $30.49 | 2019-2020 | |
| Genentech USA, INC. | $22.36 | 2021 | |
| Tactile Systems Technology INC | $12.42 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.